This post is from a suggested group
The Evolution of Drug Delivery Systems: From Passive Liposomes to Active, Programmed Nanobots for Enhanced Therapeutic Outcomes
The initial foray of nanotechnology into the pharmaceutical sector, which laid the groundwork for modern nanobots, was centered on developing passive drug delivery systems, such as liposomes and polymeric nanoparticles, to improve the solubility and pharmacokinetics of existing drugs. These early formulations focused on enhancing drug stability and increasing bioavailability by encapsulating the drug molecule, a technique that often relied on the Enhanced Permeability and Retention (EPR) effect for passive accumulation in tumor tissues. While successful in reducing side effects and improving efficacy compared to free-drug administration, these systems were inherently limited by their passive nature. The modern evolution of nanobots represents a radical shift towards active and programmed delivery, creating systems that can be externally controlled and internally responsive, significantly enhancing therapeutic outcomes. Active nanobots are designed to cross biological barriers, like…